Estrogen receptor ligands. Part 14: Application of novel antagonist side chains to existing platforms

Bioorganic & Medicinal Chemistry Letters
2005.0

Abstract

Two novel side chains which had previously been found to enhance antagonist activity in the dihydrobenzoxathiin SERM series were applied to three existing platforms. The novel side chains did not improve the antagonist activity of the existing platforms.

DOI： 10.1016/j.bmcl.2005.08.084

Knowledge Graph

Similar Paper

Estrogen receptor ligands. Part 14: Application of novel antagonist side chains to existing platforms
Bioorganic & Medicinal Chemistry Letters 2005.0
Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain
Bioorganic & Medicinal Chemistry Letters 2005.0
Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers
Bioorganic & Medicinal Chemistry Letters 2005.0
Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains
Bioorganic & Medicinal Chemistry Letters 2004.0
Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains
Bioorganic & Medicinal Chemistry Letters 2004.0
Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs
Bioorganic & Medicinal Chemistry Letters 2004.0
Estrogen receptor ligands. Part 3: The SAR of dihydrobenzoxathiin SERMs
Bioorganic & Medicinal Chemistry Letters 2004.0
Tetrahydroquinoline-Based selective estrogen receptor modulators (SERMs)
Bioorganic & Medicinal Chemistry Letters 2003.0
Estrogen Receptor Ligands. II. Discovery of Benzoxathiins as Potent, Selective Estrogen Receptor α Modulators
Journal of Medicinal Chemistry 2004.0
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs
Bioorganic & Medicinal Chemistry Letters 2005.0